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Abstract
Background: A major concern of cancer chemotherapy is the side effects caused by the non-specific targeting of both
normal and cancerous cells by therapeutic drugs. Much emphasis has been placed on discovering new compounds that
target tumour cells more efficiently and selectively with minimal toxic effects on normal cells.
Methodology/Principal Findings: The cytotoxic effect of thymoquinone, a component derived from the plant Nigella sativa,
was tested on human glioblastoma and normal cells. Our findings demonstrated that glioblastoma cells were more sensitive
to thymoquinone-induced antiproliferative effects. Thymoquinone induced DNA damage, cell cycle arrest and apoptosis in
the glioblastoma cells. It was also observed that thymoquinone facilitated telomere attrition by inhibiting the activity of
telomerase. In addition to these, we investigated the role of DNA-PKcs on thymoquinone mediated changes in telomere
length. Telomeres in glioblastoma cells with DNA-PKcs were more sensitive to thymoquinone mediated effects as compared
to those cells deficient in DNA-PKcs.
Conclusions/Significance: Our results indicate that thymoquinone induces DNA damage, telomere attrition by inhibiting
telomerase and cell death in glioblastoma cells. Telomere shortening was found to be dependent on the status of DNA-
PKcs. Collectively, these data suggest that thymoquinone could be useful as a potential chemotherapeutic agent in the
management for brain tumours.
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Introduction
A major concern of cancer chemotherapy is the side effects
induced by the non-specific targeting of both normal and cancerous
cells by chemotherapeutic drugs. Much emphasis has been placed
on discovering new compounds that specifically target cancer cells
with minimal toxicity to normal cells. Recently various natural
compounds have been shown to be promising chemotherapeutic
agents with lesser cytotoxicity to the normal cells [1]. Thymoqui-
none (TQ) is the main active constituent found in the crude extracts
of the seeds of Nigella sativa Linn. and studies have shown that TQ
possesses antineoplastic properties [2,3,4]. Decrease in cell survival
with pro-apoptotic properties have also been identified in various
cancer cell lines including the canine osteosarcoma cells, human
colon carcinoma, breast adenocarcinoma cells, and the ovarian
adenocarcinoma cells [5]. TQ has been demonstrated as a cytotoxic
agent in several multi-drug resistant human tumour cell lines [6].
However, the underlying molecular mechanism of its anticancer
properties is not well understood.
Telomerase activity is generally absent in human somatic cells
whereas in 90% of tumour cells, activation of telomerase prevents
telomere shortening and thus allows for unlimited replicative
capability [7]. Telomerase inhibition therefore presents an
attractive target for cancer therapeutics [8,9]. Early events in the
development of glioblastoma include the re-activation of human
telomerase reverse transcriptase (hTERT) [10]. In addition, a p53
mutation also contributes to the progression to malignancy in
gliomas [11]. Studies have shown that human glioblastoma cells
deficient in DNA-PK activity are able to recruit a slow, error
prone repair process that can result in the increased formation of
chromosome aberrations [12]. DNA-dependent protein kinase is a
nuclear, serine/threonine protein kinase consisting of a 470-kDa
catalytic subunit (DNA-PKcs) and a heterodimeric regulatory
complex ku70/80.This enzyme is essential for the repair of DNA
double-strand breaks and it mediates repair via phosphorylation of
downstream DNA binding proteins such as p53, DNA ligase IV
and transcription factors such as Fos, Jun, myc, Oct1, NF-kappa
B, and RNA polymerase H [13,14].
Brain tumours have low prognosis with survival rate of only few
months and traditional therapy methods such as surgery,
radiotherapy and chemotherapy have low efficacy. Furthermore,
brain tumour cells are resistant to numerous chemotherapeutic
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increase the sensitivity of DNA damaging chemotherapeutic
agents. In this study, we sought to determine the anti-cancer
effects of TQ in a defined DNA repair proficient and DNA repair
deficient cells and its impact on the telomerase-telomere status in
DNA-PKcs proficient and deficient human brain cancer cells. We
performed in vitro studies to determine the level of cytotoxicity
induced by TQ in human glioblastoma cells. In addition, the
effects of TQ on both the telomerase activity and telomere length
in cancer cells with different DNA-PK status were also
investigated. Our findings demonstrate that at selective dose of
TQ, glioblastoma cells were more sensitive to TQ-induced
damage as compared to normal cells as indicated by the higher
levels of apoptosis and reduced cell viability. Increased expression
of pro-apoptotic proteins Bax and cytochrome c were also
observed in glioblastoma cells. In addition, DNA-PKcs proficient
glioblastoma cells were more sensitive to TQ as compared to
DNA-PKcs deficient glioblastoma cells.
Materials and Methods
Cells, Cell Culture and Drug Treatment
Two human glioblastoma cell lines, M059K (CRL-2365) and
M059J (CRL-2366) (American Type Culture Collection, USA)
were used in the study. M059J cells lack DNA-PKcs activity while
M059K cells express normal levels of DNA-PKcs. Glioblastoma
cells were cultured in Dulbecco’s Modified Eagles Medium
(DMEM) supplemented with 10% heat inactivated foetal bovine
serum (Hyclone, USA) and 100 U/ml of penicillin/streptomycin
(Gibco, USA). hTERT immortalised human foreskin fibroblasts
(hTERT-BJ1; Clontech, USA) were cultured in 4:1 ratio of
DMEM and Medium 199, supplemented with 10% foetal bovine
serum, 100 U/ml of penicillin/streptomycin, 1% sodium pyruvate
and 2% L-glutamine (Gibco, USA). Normal human lung
fibroblasts (IMR-90; Coriell Cell Repositories, USA) were cultured
in Minimal Essential Medium (Gibco, Invitrogen, USA) supple-
mented with 15% foetal bovine serum, 100 U/ml of penicillin/
streptomycin, 1% vitamins and 1% essential and non-essential
amino acids. All cells were maintained in a humidified 5% CO2
incubator at 37uC. Stock solution of thymoquinone (TQ) (Sigma,
USA) and a DNA-PKcs inhibitor NU7026 (Calbiochem, USA)
[15] were prepared in dimethyl sulfoxide (DMSO) and suitable
working concentrations were made from the stock using complete
medium. Exponentially growing cells were treated with 0 to
200 mM TQ for 24 hours following which 25 and 50 mM doses
were selected for subsequent studies.
Assay for cell viability
Following TQ treatment, attached cells were washed once with
phosphate buffered saline (PBS). Crystal violet solution (0.75%
crystal violet in 50% ethanol: distilled water with 1.75%
formaldehyde and 0.25% NaCl), which stains DNA by binding
electrostatically to nuclear proteins was added to the wells and
incubated for 20 minutes at room temperature. Following PBS
washes, to remove excess crystal violet solution, wells were air
dried. Sodium dodecyl sulphate: PBS solution was added to lyse
the cells and solubilise the dye. We measured the amount of crystal
violet taken up by cells at 595 nm absorbance using an automated
ELISA reader.
Cell cycle analysis
Following TQ treatment, cells were harvested, washed in 0.1%
BSA: PBS, fixed in 70% ethanol: 1 6 PBS, and stained with
propidium iodide (Sigma, USA): RNase A (Roche, USA) (2 mg
propidium iodide and 2 mg RNaseA/100 mL 0.1% BSA in 1 6
PBS). Samples were analysed by flow cytometry (FACSCalibur
TM,
Becton Dickinson, USA) at 488 nm excitation l and 610 nm
emission l. A total of 10,000 events were captured. Data obtained
was analysed using WINMDI software.
Analysis for apoptosis and necrosis
Untreated and TQ-treated glioblastoma cells were stained with
an Annexin V antibody and propidium iodide using Annexin-V-
FITC staining kit (Sigma, USA). Samples were then analysed by
flow cytometry. A total of 10,000 events per sample was obtained
and the data was analysed using WINMDI software.
Protein estimation by Western blot analysis
Total cellular proteins were isolated using RIPA (radio-
immunoprecipitation assay) buffer (1% nonidet P-40, 1% sodium
deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phos-
phate, 2 mM EDTA, 50 mM sodium fluoride, 0.2 mM sodium
vanadate and 100 U/ml aprotinin, pH 7.2) from control and
treated cells. The whole cell lysate was recovered by centrifugation
at 14,000 rpm for 10 minutes. Protein concentration was
determined by the bicinchoninic acid method using an assay kit
(Pierce Biotechnology, USA) with bovine serum albumin as a
standard. Western blot analyses of cell cycle regulatory proteins
(p53, p21), pro-apoptotic factors (Bax, Cytochrome c), hTERT
and b-actin (Santa Cruz Biotechnology, USA) were performed
using specific antibodies.
Assessment of DNA damage
TQ induced DNA damage was evaluated using alkaline single
cell gel electrophoresis (Comet) assay. Following treatment with
TQ for 24 hours, the extent of total DNA damage was evaluated
as described previously [16]. Cells were harvested and resus-
pended in Hank’s Balanced Salt Solution (Sigma, USA) with 10%
DMSO and 0.5 M EDTA. The cell suspension was then
suspended in 0.7% low melting agarose at 37uC (Conda, Spain),
and layered on to comet slides (Trevigen, USA). The cells were
then lysed in lysis solution containing 2.5 M NaCl, 100 mM
pH 8.0 EDTA, 10 mM Tris-HCL, 1% Triton –X at 4uC for
1 hour. Denaturation was carried out for 40 minutes, in chilled
alkaline electrophoresis buffer (pH 13.0–13.7). Electrophoresis was
subsequently carried out for 20 minutes. Slides were immersed in
neutralization buffer (500 Mm Tris-HCL, pH 7.4), dehydrated,
dried and stained with SYBR Green dye (Trevigen) and scored
with Comet Analysis Software (Metasystems, Germany). The
images were captured using Zeiss Axioplan 2 imaging fluorescence
microscope (Carl Zeiss, Germany) equipped with triple band filter.
Fifty comets per sample were randomly selected and analysed. The
extent of DNA damage was expressed as tail moment, which
corresponded to the fraction of the DNA in the tail of the comet.
Measurement of Telomerase Activity
Telomerase activity was assessed using Telomeric Repeat
Amplification Protocol (TRAP) using TRAPezeH XL Telomerase
Detection Kit (Chemicon International, USA). All steps were done
according to the manufacturer’s instructions with some modifica-
tions. Briefly, total protein was extracted using CHAPS lysis buffer
provided and 1.5 mg protein was treated with 1 ml/ml RNase
inhibitor to perform PCR reaction. The PCR was initiated by
using the telomerase mediated elongation products (i.e. the
telomeric DNA repeats) as template. Subsequently normal PCR
cycle was performed using primer pairs with quenched fluorescein
to amplify the telomeric DNA repeats. Fluorescence signals were
Cytotoxicity of Thymoquinone
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the fluorescence signals were measured by fluorescence multi-well
plate reader. Fluorescence signals of PCR products were measured
using fluorescence plate reader TECAN SpectraFluor Plus.
Telomere length analysis
Telomere Restriction Fragment (TRF) Length Analysis.
DNA extraction was performed according to the manufacturers’
protocol using DNeasy Tissue Kit (Qiagen, USA). The telomere
restriction fragment length analysis assay was performed using
Telo-TAGGG Length Assay Kit (Roche Applied Science, USA).
Two micrograms of pure genomic DNA was digested with Hinf1
and Rsa1 restriction enzymes for 2 hours at 37uC. These
restriction enzymes digest the whole genomic DNA except the
sub-telomeric and telomeric regions. Digested DNA fragments
were separated by gel electrophoresis in 0.8% agarose gel at 60 V
for 3 hours, transferred via overnight Southern blot onto a
nylon membrane and cross-linked onto the membrane using a UV
cross-linker (Stratagene, USA). Telomere restriction fragments
were hybridised with telomere-specific digoxigenin-labelled
probe and incubated with Anti-DIG alkaline phosphatase and
tetramethylbenzidine according to manufacturer’s protocol. The
chemiluminescence signals were scanned by the Kodak Gel
imaging system and analyzed by the Kodak imaging software to
calculate the quantitative measurements of the mean TRF length.
Quantitative Fluorescence in situ Hybridisation (qFISH)
Analysis. Cells were arrested at mitosis by treatment with
colcemid (0.1 mg/ml). Cells were subsequently incubated with a
hypotonic solution of potassium chloride at 37uC for 15 minutes
followed by fixation in Carnoy’s fixative. Quantitative fluorescence
in situ hybridisation (qFISH) was performed using telomere
sequence-specific peptide nucleic acid (PNA) probe labelled with
Cy3 as described [17,18]. Metaphase spreads for different samples
were hybridised simultaneously. To avoid selection bias, good and
well spread metaphases were randomly chosen for analysis. Images
were acquired on the same day (within four hours) for all the
samples using the Zeiss Axioplan 2 imaging fluorescence
microscope. Fluorescence intensity of telomere signals was
measured in 10–15 metaphases using the in situ imaging software
(Metasystems, Germany).
Gene expression analysis
The total RNA was extracted from M059K and M059J cells
using QIAmp RNA Blood Mini Kit (Qiagen, Hilden, Germany).
The extracted RNA was quantified using NanoDrop 1000 (Thermo
Scientific, USA). RNA integrity was checked using Bio-Analyzer
(Agilent Technologies, Inc., USA). Five hundred nanograms of
extracted RNA from each sample were used for gene expression
study. TotalPrep RNA Amplification Kit (Ambion Inc., TX, USA)
was used for cRNA amplification process. The biotinylated
amplified RNA thus generated was used for hybridization with
HumanRef8 V3.0, Human Whole-Genome Expression BeadChips
(Illumina Inc., USA) for 16 hours at 58uC. After the incubation
period, the arrays were washed and stained with Streptavidin-Cy3
(GE Healthcare, Bio-Sciences, UK). Illumina Bead Array Reader
was used to scan the arrays. The array data thus obtained after
scanning was imported and analysed using PartekH Genomics
Suite
TM (Partek GS) (Partek Incorporated, MO, USA).
Chromosome analysis by multicolour fluorescence in situ
hybridisation (mFISH)
The experimental procedure is outlined in our earlier
publications [19,20]. Chromosome paints were obtained from
MetaSystems GmbH, Germany. After pepsin treatment (1 g/
50 ml; Sigma) for about 2 minutes at 37uC the chromosomes were
post-fixed in 1% formaldehyde in 1XPBS with 50 mM MgCl2 for
10 minutes at room temperature. The chromosomes are stabilised
in SSC prior to the denaturation and were subsequently denatured
with a basal solution (0.07 N NaOH). Afterwards, the chromo-
somes were rinsed in SSC buffer again to stop the denaturation
process and to stabilize their structure. The probe cocktail was
denatured 75uC for 5 minutes. The probe was allowed to pre-
hybridise for half an hour at 37uC to reduce unspecific binding of
short or repetitive DNA pieces. The denatured and prehybridised
probe cocktail was applied onto the denatured chromosome
preparation, overlaid with a coverslip and sealed with rubber
cement. The slides were then incubated at 37uC in a humidified
chamber for 72 hours. Post-hybridisation washing was done in
1xSSC at 75uC for 5 minutes after removing the coverslips. Slides
were incubated in 4xSSCT for 5 minutes and blocked with
blocking reagent at 37uC for 10 minutes. Subsequently, slides were
incubated with detection 1+3 reagent to detect Cy5 which is
indirectly labelled. Slides were then counterstained with DAPI
(Metasystems). Microscopic analysis was performed using an
Axioplan II imaging microscope (Carl Zeiss) with an HBO-103
mercury lamp and filter sets for FITC, Cy3.5, Texas Red, Cy5,
Aqua, and DAPI. Images were captured, processed, and analyzed
using ISIS mFISH imaging software (MetaSystems). In the mFISH
technique, all 23 chromosomes (1–22 and X) are each painted in a
different colour, using combinatorial labelling, so that any
interchromosomal translocations are observed as colour junctions
on individual chromosomes.
Statistical Analysis
Statistical significance in the data sets was assessed by Student’s
t-test using Microsoft Excel 2003 (Microsoft Corporation, USA)
and two-way ANOVA using Graphpad Prism. The difference was
considered to be statistically significant when p,0.05.
Results
Thymoquinone reduced the viability of the human brain
cancer cells more effectively than non-cancerous cells
Exposure to TQ resulted in a dose dependent decrease in cell
survival in all the cell lines from 0 to 50 mM of TQ (Figure 1A).
The glioblastoma cells displayed greater TQ induced cell death
compared to the normal cells tested. The greatest difference in
survival between the normal cells and glioblastoma cells following
TQ treatment occurred at concentration of 50 mM. The death
induced in glioblastoma cells was significantly higher than normal
(IMR90) cells (Figure 1A). Based on the viability trend obtained,
50 mM was chosen for subsequent assays. Furthermore at 50 mM,
DNA-PKcs proficient M059K cells were more sensitive TQ-
induced cell death as compared to DNA-PKcs deficient (M059J)
cells.
To determine whether the growth inhibition by TQ involves
cell death or growth arrest, cells stained with PI were subjected to
FACS analysis. Increase in sub-G1 population, an indication of
apoptotic death, was observed only in telomerase positive cells
(Figure 1B). At 50 mM TQ, the glioblastoma cells exhibited higher
percentage of apoptotic cell death (sub-G1 population) than the
normal IMR90 cells (Figure 1B). There was a two fold increase in
glioblastoma cell death following TQ treatment compared to
untreated controls. In addition, M059J cells exhibited G2/M
arrest (about 10%). In contrast, a three-fold increase in S-phase
population in normal cells treated with TQ was observed.
However, in telomerase positive (hTERT-BJ1) cells, there was a
Cytotoxicity of Thymoquinone
PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12124Figure1.Thymoquinoneinducescelldeathinhumanglioblastomacells.(A)Cell viability ofthevarious celltypes after24 hourtreatmentwithTQ
at the different concentrations is shown. The percentage cell viability was normalised against the DMSO controls (0 mM) for each cell type. Mean and
standarddeviations of thethree independent experimentsare shown. (B) Cell cycle profiles ofthe IMR 90,hTERT-BJ1 andglioblastoma cells without (0 mM)
or withTQ (50 mM) treatmentas measured bypropidium iodide staining. (C) Changes in level ofcell cycle regulatory proteinsin the cell lines tested. Whole
cells were lysed and equal amounts of proteins were separated using 4–20% SDS-PAGE, transferred to PVDF membrane and immunoreacted with
antibodies against p53 and p21. b-actin was used as loading control.
doi:10.1371/journal.pone.0012124.g001
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Impairment of growth in normal cells following TQ treatment
was accompanied by the increase in p53 and p21 proteins
(Figure 1C). However, hTERT-BJ1 cells showed an increase in
p53 protein level followed by a decrease in the expression of cyclin
dependent kinase inhibitor protein, p21.
Thymoquinone induces apoptotic death in glioblastoma
cells
As shown in Figure 2A, all tested cells treated with 50 mMT Q
exhibited change in morphology compared to their respective
controls. However, more floating and rounded cells which suggest
dying cells were observed in glioblastoma cells. Expression of pro-
apoptotic Bax protein level increased only in glioblastoma cells
(M059K and M059J) following 50 mM TQ (Figure 2B). To
investigate the apoptotic cascades involved in the TQ-induced cell
death in glioblastoma cells, total and cytosolic cytochrome c
protein level was measured. The level of cytosolic cytochrome c,
which is critical for the initiation of apoptosis, was significantly
increased in M059K cells (Figure 2B). Cell death following TQ
treatment in glioblastoma cells was predominantly due to
apoptosis as demonstrated by the increase in cell population
showing positive staining for Annexin V (Figure 2C).
Thymoquinone produces significant DNA damage in a
dose dependent manner
Single-cell gel electrophoresis (known as comet assay) under
alkaline condition (pH.13) was used to determine the DNA
Figure 2. Thymoquinone treatment produces apoptosis in human glioblastoma cells. (A) Morphological appearance of cells treated with
TQ (50 mM) for 24 hours. (B) Changes in the level pro-apoptotic proteins Bax and cytochrome c in different cell types used in the study. (C) FACS
profiles of staining for Annexin V and propidium iodide to determine apoptosis and necrosis. (l) M059K (untreated) (ll) M059K (TQ treated) (lll) M059J
(untreated) and (IV) M059J (TQ treated).
doi:10.1371/journal.pone.0012124.g002
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DNA damage such as double-strand breaks, single-strand breaks
and alkali labile sites were measured using comet assay.
Representative images of comet analysis were shown in
Figure 3A. Following TQ treatment, all cells showed a dose
dependent increase in DNA damage compared to respective
controls (Figure 3B). At 50 mM TQ, M059J cells were less
susceptible to TQ induced DNA damage compared to M059K
cells. Interestingly, DNA damage was lower at 25 mMT Qi n
normal fibroblast cells (IMR90 and hTERT-BJ1) than in
glioblastoma cells. On the contrary, TQ treated M059J cells
showed significant DNA damage unlike TQ treated M059K cells
that displayed minimal increase when compared to respective
untreated control cells at 25 mM TQ (Figure 3B). The DNA
damage data obtained by comet assay were supported by higher
micronuclei detected in the TQ treated cells (data not shown)
which are suggestive of both DNA damage and resulting
chromosome instability.
Thymoquinone induces telomere attrition
Our findings from telomerase positive hTERT-BJ1 fibroblasts
demonstrate increased sensitivity to TQ induced anti-proliferative
effect as compared to normal cells. To determine whether the
decrease in cell proliferation was linked to effect of TQ on
telomerase activity, we evaluated the level of telomerase activity in
cells with and without TQ treatment. Firstly, the basal level of
telomerase activity in the different cells was investigated. As
expected, telomerase activity was negligible in normal lung
fibroblasts (IMR90), while the hTERT-BJ1 and glioblastoma cells
showed positive telomerase activity (Figure 4A). M059J cells
displayed lower telomerase activity compared to M059K cells. At
24 hours post-TQ treatment (50 mM), a significant decrease in
telomerase activity was detected in hTERT-BJ1 and M059K but
not in M059J cells (Figure 4B). Furthermore, we have observed
that there is a decrease in the expression of hTERT following TQ
treatment (Figure 4C) demonstrating a novel effect of TQ on
telomere-telomerase complex.
Since, telomerase is pivotal for the maintenance of telomere
length, we monitored changes in telomere length, if any, following
TQ treatment using TRF assay. Lower dose (25 mM) of TQ was
used for an extended time of 15 days in glioblastoma cells and
telomere length was measured at 4 and 15 days of treatment. Only
glioblastoma cells were evaluated for telomere length analysis
because our findings have shown that the level of TQ- induced
DNA damage (Figure 3) and anti-proliferative effect (Figure 1) of
TQ were more pronounced in glioblastoma cells as compared to
normal cells. Short term treatment for 4 days with 25 mM TQ did
not show detectable change in telomere length (Figure 4D).
Following TQ (25 mM) treatment for 15 days, M059K cells
showed greater telomere shortening compared to M059J cells
(Figure 4E). Thus the data suggest that TQ disrupts telomere
length maintenance by inhibiting the activity of telomerase over
time in cancer cells. However, M059J cells deficient in DNA-PKcs
were less sensitive to TQ mediated effects on telomere length
maintenance. Therefore, we investigated the role of DNA-PKcs in
TQ mediated effects on telomeres.
Role of DNA-PKcs in thymoquinone mediated telomere
attrition
In order to understand the influence of DNA-PKcs on the TQ
mediated effects on telomeres in the glioblastoma cells, a two
pronged approach was taken. Firstly, we profiled M059K and
M059J cells for inherent similarities and differences by gene
expression profiling and karyotyping. Secondly, we validated the
role of DNA-PKcs by the using its specific pharmacological
inhibitor, NU7026 [15].
It is reported that M059J cells were derived from M059K cells
and were deficient in DNA-PKcs [21,22]. A detailed characterisa-
tion and gene expression profiles of these cells have not been
reported so far. mFISH was performed to karyotype M059K and
M059J cells. Modal chromosome number for M059K cell type is
to be 75 (with a range of 65 to 79 (www.atcc.org) with a polyploidy
rate of 22% whereas M059J cells reported to be aneuploid (www.
atcc.org). Representative mFISH images of M059K and M059J
metaphase spreads are shown in Figure 5A. Our analysis has
revealed that average chromosome number for M059K is 87 and
that of M059J is 68. The karyotypes clearly indicate complex
chromosomal rearrangements like reciprocal and non-reciprocal
translocations in both the cell types. Recurrent chromosomal
translocations such as t(8;21;5), t(1;21;6), t(5;21) and t(4;17;22;21;9)
were detected in M059K cells. Likewise, translocations such as
t(7;16;14); t(11;12); t(8;6); 2 copies of t(9;21;3), and two copies of
t(9;21;19) were detected in M059J cells. Translocations such as
t(16;17), t(16;10) and multiples copies of t(9;21) were commonly
seen in both the cell types. At this moment, it is not possible for us
to conclude that the translocations detected in M059J cells are
result of defective DNA-PKcs. Following microarray analysis to
determine the gene expression profiles of M059K and M059J cells,
we found that a total of 587 genes (approximately 2% of the genes
analysed) were differentially expressed based on the set criteria
Figure 3. Induction of DNA damage in thymoquinone treated
glioblastoma cells. DNA damage as measured by the comet assay in
different cell types following treatment with thymoquinone at 25 mM
and 50 mM for 24 hours. The damage distribution was measured as tail
moment (product of tail length and fraction of DNA). (A) Representative
of SYBR Green-stained comets prepared from control (I) and TQ treated
glioblastoma cells (II and III). Varying degree of damage could be seen
(II and III). (B) Extent of damage is presented by mean tail moment
(product of tail length and fraction of DNA) in the attached cells. (*)
indicates that the change in DNA damage with respect to control is
statistically significant, i.e. p-value ,0.05. The increase in DNA damage
between 25 mM and 50 mM was also found to be statistically significant
for all samples. Tail moment (in microns) is given. Mean and standard
error from three independent experiments are shown.
doi:10.1371/journal.pone.0012124.g003
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M059K and M059J cells. (B) Percentage change in telomerase activity relative to their respective untreated controls following exposure to 50 mMT Qf o r
24 hours. (C) Expression of hTERT following TQ treatment (50 mM) for 24 hours. Telomere restriction fragment analysis for telomere length measurement in
glioblastoma cells following 4 days (D) and 15 days (E) treatment with 25 mM TQ. Changes in telomere length are expressed as percentage with respect to
its controls. Graph shows mean and standard error from three independent experiments and TRF blot shown is a representative from three independent
experiments. (*) indicates statistical significance, p,0.05.
doi:10.1371/journal.pone.0012124.g004
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suggest that genetic differences exist, but minimal, among the two
different cell types (data not shown).
As shown in Figures 4B and D, cells deficient in DNA-PKcs
(M059J) exhibited relatively lesser TQ-mediated telomerase
inhibition and telomere attrition. To further understand the role
of DNA-PKcs in the differential effect of TQ on telomere-
telomerase homeostasis, we used NU7026, a DNA-PKcs specific
pharmacological inhibitor along with TQ. We observed that TQ
induced telomerase inhibition in M059K cells which were pre-
treated with NU7026 was 10% lesser than TQ alone treatment
(TQ - 23% inhibition and NU7026 + TQ - 13% inhibition)
(Figure 6A). Similar trend was seen with regards to TQ mediated
telomere attrition and NU7026 was found to slow this process
down in M059K cells (Figures 6B–D). These results were
comparable to those seen in M059J cells (Figures 4A–E)
highlighting the role of DNA-PKcs in TQ mediated telomere
shortening in glioblastoma cells. We hypothesised that telomere
attrition resulted from TQ treatment in glioblastoma cells may
produce dysfunctional telomeres. Treatment with drugs may
generate aberrant telomeres [23] due to dysfunctional telomeres
and replication stress. To determine whether telomerase inhibition
and telomere shortening in TQ treated M059K cells has resulted
in telomere dysfunction, we analysed fragile telomeres in M059K
cells following TQ exposure with or without NU7026. In
metaphase spreads, fragile or aberrant telomeres are characterised
by the presence of undetectable telomeres at chromosome ends,
telomeric doublets and different signal intensities on sister
chromatids. Representative metaphase images with fragile telo-
meres are shown in Figure 6E. Number of aberrant telomeres per
cell displayed in Figure 6F corresponded to telomere attrition and
telomerase inhibition (Figures 6A–D). TQ alone has resulted in
elevated number of dysfunctional telomeres, while combined
treatment produced a lower number of dysfunctional telomeres
compared to TQ single treatment but higher than the NU7026
alone treatment (Figure 6F).
Discussion
There has been an increasing interest in natural plant products
as potential chemotherapy in human tumours due to their lower
cytotoxic effects on the normal cellular system [1]. Limited
number of reports is available in the literature on the growth
inhibitory and pro-apoptotic effects of TQ in tumour cells [5,24].
Moreover, effect of TQ on telomerase activity and telomere length
in cancer cells has not yet been explored. We demonstrate in this
study that TQ exhibits specific cytotoxicity in cancer cells at
selective doses. Glioblastoma cells were found to be more sensitive
to TQ-induced anti-proliferative effect as compared to normal
cells (IMR90 and hTERT-BJ1). Reduction in cell viability was
attributed to the induction of apoptosis by TQ in glioblastoma
cells as evidenced by higher percentage of cells with Annexin V
staining and more cells in sub-G1 phase of the cell cycle following
treatment.
Majority of the cancer chemotherapy drugs function as DNA
damaging agents that subsequently trigger cell death. In this study,
we show that TQ induces DNA damage and cell death in
glioblastoma cells. When DNA damages are irreparable, the cells
undergo apoptosis. Induction of DNA damage in normal cells led
to p53 mediated p21 triggered growth inhibitory effects which
Figure 5. Chromosome rearrangements and gene expression
profiles in M059K and M059J cells. (A) Cells were arrested at
metaphase and chromosome spreads were subjected to multicolour
fluorescence in situ hybridisation (mFISH). Representative mFISH
karyotypes of M059K and M059J cells. Note the higher number of
chromosome re-arrangements in both the cell types. Recurrent
chromosome translocations are numbered as follows: (1) - t(8;21;5);
(2) - t(16:10); (3)- t(16; 17); (4) - t(9;21;3); (5) – t(9;21;19); (6) – t(14;Y). ((B)
Differential gene expression profiles in M059K and M059J cells. Volcano
plot indicates differentially regulated genes. Clusters in blue indicate
genes differentially genes (p,0.05; 1 way ANOVA). Black bold lines
(X axis) indicate fold change cut off of 2.
doi:10.1371/journal.pone.0012124.g005
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untreated controls following exposure to 50 mM TQ for 24 hours with and without DNA-PKcs inhibitor, NU7026 (10 mM). Telomere length
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glioblastoma cell growth and induced cell killing by apoptosis.
We believe that the apoptotic effect of TQ was modulated by
increased expression of Bax and cytochrome c proteins. Apoptosis
via mitochondrial pathway involves the release of the inter-
membrane mitochondrial proteins, cytochrome c into cytosol and
subsequently triggering a cascade of proteolytic events [25]. Based
on our findings, we speculate that TQ induces apoptosis in
glioblastoma cells proficient in DNA-PKcs by the above-
mentioned mechanism, which was evidenced by an increase in
the cytosolic cytochrome c level. Studies have shown that TQ
induces apoptosis by both p53-dependent [24] and p53-indepen-
dent pathways [26]. Our data agrees with the latter wherein cell
death triggered by TQ in glioblastoma was p53 independent as
shown by the minimal change in expression of p53.
Tumour cells develop resistance to chemotherapy or radiother-
apy over time via genetic alteration resulting in less effective
treatment. DNA-PKcs is essential for DNA double strand breaks
repair and maintenance of genomic integrity [27]. Studies have
shown that DNA double strand break repair in cells deficient in
DNA-PKcs usually results in high frequencies of mis-repair,
chromosome aberrations and complex changes [12]. In our study,
we show that glioblastoma cells with different DNA-PKcs status
respond differently to TQ exposure. DNA-PKcs deficient
glioblastoma cells displayed significant cell cycle arrest at G2/M
phase in addition to cell death. Significant level of TQ induced
DNA damage was also observed in these cells at lower dose of TQ.
This observation correlates with earlier findings that only DNA-
PKcs deficient glioblastoma cells showed G2/M accumulation
upon treatment with DNA double strand break inducing agents
[28]. Moreover, the frequency of binucleated cells with micronu-
clei, indicative of chromosome instability, was higher in DNA-
PKcs deficient glioblastoma cells as compared to DNA-PKcs
proficient glioblastoma cells (data not shown). This points out that
although DNA-PKcs deficient glioblastoma cells were less sensitive
to TQ induced cytotoxicity as compared to DNA-PKcs proficient
glioblastoma cells, greater extent of genomic instability could be
detected in DNA-PKcs deficient glioblastoma which might be due
to the inefficient non-homologous end joining DNA repair
processes. The increased cell death shown in DNA-PKcs proficient
glioblastoma cells supports the view that TQ targets DNA-PKcs
proficient glioblastoma cells and that DNA-PKcs activation may
play a role in apoptosis. This finding corroborates an earlier study,
which showed a greater resistance of DNA-PKcs deficient
glioblastoma cells to cell death as compared to DNA-PKcs
proficient glioblastoma [29].
Interestingly, telomerase positive human foreskin fibroblast cells
(hTERT-BJ1) were also more sensitive to growth inhibitory effect
of TQ as compared to normal lung fibroblasts (IMR90).
Telomerase activity was evaluated following TQ treatment to
hTERT-BJ1 cells to determine whether increased sensitivity was
due to telomerase inhibition. Telomerase is essential in regulating
telomere length in immortal cells as well as maintaining the
proliferative capacity of cells [8,30,31,32]. Telomerase may play a
central role in cellular resistance to apoptosis of cancer cells and
inhibition of telomerase may induce apoptosis [33,34]. Telomere
dysfunction, whether due to replicative shortening or experimental
disruption of telomeric DNA-protein complex structure, leads to
rapid DNA damage response which can ultimately induce
senescence and/or apoptosis [35]. Attempts are being made to
exploit this aspect in cancer therapy. In our study, for the first
time, we found that TQ significantly reduces telomerase activity
and induces telomere attrition. A significant reduction in
telomerase activity and expression of hTERT protein was
observed in hTERT-BJ1 and M059K cells and not M059J cells
following TQ treatment. Among the cancer cells, we observed that
the level of telomerase activity decreased significantly only in
DNA-PKcs proficient glioblastoma cells with respect to its
controls. Similar results were obtained with regards to TQ
mediated telomere attrition which can be attributed to the
selective inhibition of telomerase activity in DNA-PKcs proficient
cells.
The differential response of M059J and M059K gliobloastoma
cells to TQ treatment prompted us to characterise these cells to
determine whether defective DNA-PKcs status has resulted in any
specific changes in the basal genetic traits. Earlier, we had shown
that DNA-PKcs is critical for telomere capping [36,37] apart from
its function in responding to DNA damage. DNA-PKcs deficient
mouse embryonic fibroblasts displayed higher telomere fusions
and chromosome instability [36]. Considering the role of DNA-
PKcs at telomeres, we went on to validate our observation on the
role of DNA-PKcs in TQ mediated telomere attrition. Subtle
differences in the karyotypes of M059K and M059J cells were
identified and these cells harbour several recurrent complex
chromosomal rearrangements. In order to further the understand-
ing if the above findings, gene expression profiling was done in
these cell lines. A total 587 genes (,2% of the total genes profiled)
were differentially expressed based on the set analysis criteria.
However, more work needs to be done to validate the functional
relevance of these genes and whether they are dependent on the
status of DNA-PKcs. All in all, there are differences in the
chromosome rearrangements and gene expression profiles of two
glioblastoma cell types used in the study but the gross genetic
changes might be minimal in the two glioblastoma cell types used
in the study. Telomere-mediated chromosome instability was
commonly detected in cells deficient in DNA-PKcs [36,38,39,40].
Therefore, we believe that defective DNA-PKcs might be the
cause of differential response to TQ in our study.
In order to validate and substantiate our data on DNA-PKcs
deficient M059J cells, we used NU7026 to inhibit the kinase
activity of DNA-PKcs in M059K cells to study the telomere
attrition following TQ treatment. Pre-treatment with NU7026 in
M059K cells produced a similar response to that of M059J cells for
TQ exposure. Therefore, it is clear that TQ mediated effects on
telomerase and telomere length were significantly reduced in the
absence of DNA-PKcs achieved either by using a DNA-PKcs
deficient cell type or by functional inhibition of its kinase activity in
DNA-PKcs proficient cells. We therefore, suggest the DNA-PKcs
activity is rather relevant to mediate the above observed TQ
effects. It was recently reported that the absence of DNA-PKcs
increases the spontaneous telomere attrition rate in telomerase
knockout (mTERC
2/2) mice [41]. Based on our results, we can
measurements using TRF analysis (B and D) and qFISH (C) in glioblastoma cells following 15 day-treatment with 25 mM TQ and NU7026 (10 mM).
Changes in telomere length by TRF are expressed as percentage with respect to its controls (D). Mean 6 standard error from two independent
experiments are shown. * p,0.05. (C) Telomere fluorescence intensity (TFI) values from qFISH analysis are displayed for different samples. (E–F)
Telomere dysfunction induced by 15-day treatment with TQ (25 mM) in DNA-PKcs inhibited (NU7026, 10 mM) M059K cells. (E) Partial metaphase
spreads from M059K cells displaying chromosomes stained for telomeres (red) and centromeres (green) with telomeric doublets (1), different signal
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specifically facilitate TQ effects. Further investigation is warranted
to find out the factors downstream of DNA-PKcs which are
required for external agent induced telomere attrition in human
cells. In conclusion, we demonstrate that TQ induces higher
induction of apoptosis in glioblastoma cells. Furthermore, we
could detect telomerase inhibition, telomere attrition, increased
DNA damage and apoptosis by TQ in DNA-PKcs proficient
glioblastoma cells as compared to DNA-PKcs deficient glioblas-
toma cells. In addition, TQ also mediates apoptosis independent of
telomerase attrition as observed in DNA-PKcs deficient glioblas-
toma cells. Thus, this agent can be a potential candidate as
chemotherapeutic agent for the treatment of brain cancers.
However, detailed studies are required to profile the genome
wide effects of TQ to exploit its therapeutic potential more
effectively.
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